Europe Generic Drugs Market Size, Share and Forecast 2020-2026

Europe generic drugs market is estimated to grow at a CAGR of nearly 5.7% during the forecast period. European government initiatives to support generic producers are supporting to drive market growth. In May 2019, the European Union (EU) is taking measures to increase the competitiveness of EU manufacturers of generic drugs and biosimilar products. EU-based producers of generics and biosimilars will be entitled to produce a biosimilar or a generic version of a supplementary protection certificate (SPC)-protected drug. The new EU regulation will allow manufacturers of generic drugs that are EU based to compete with non-EU manufacturers equally. This will generate high-value jobs and increase the accessibility of generic medicines within the EU.

To Request a Sample of our Report on Europe Generic Drugs Market: https://www.omrglobal.com/request-sample/europe-generic-drugs-market

Additionally, in November 2020, the European Commission makes a draft that intends to make it easier for patients to gain access to low-cost, generic medicines. This draft could cut the revenues of major pharma companies. The European Commission will consider targeted policies that facilitate higher competition in generic and biosimilar. Removal of barriers that delays the entry of generic medicines is also expected to witness by 2022. Such kinds of initiatives will further escalate market growth.

Scope of the Europe Generic Drugs Market

Market Coverage

· Market number available for 2019-2026

· Base year- 2019

· Forecast period- 2020-2026

· Segment Covered- By Application and Route of Administration

· Countries Covered- UK, Germany, France, Spain, Italy, and Rest of Europe

· Competitive Landscape- Mylan N.V., Teva Pharmaceutical Industries Ltd., Lupin Ltd., and Novartis International AG

Recent Strategic Initiatives in the Europe Generic Drugs Market

· In November 2020, the European Medicine Agency’s (EMA) declared that it recommends granting marketing authorization for the generic drug Lenalidomide Mylan (lenalidomide). This hard capsule is indicated to treat follicular lymphoma and multiple myeloma. It is a generic version of Celgene’s Revlimid, approved in the European Union (EU) since 2007.

· In July 2019, Sandoz, a part of Novartis International AG declared the introduction of the generic cancer drug gefitinib which is intended for adult patients suffering from locally advanced or metastatic non-small cell lung cancer. It is available in 13 countries across Europe and the company will constantly widen to other countries through a phased rollout.

(Get 15% Discount on Buying this Report)

A full Report of Europe Generic Drugs Market is Available at: https://www.omrglobal.com/industry-reports/europe-generic-drugs-market

Europe Generic Drugs Market-Segmentation

By Application

· Cancer

· CVD

· Musculoskeletal Diseases

· Infectious Diseases

· Neurology

· Diabetes

· Others

By Route of Administration

· Oral

· Topical

· Injectable

· Inhaler

Europe Generic Drugs Market– Segment by Country

· Germany

· UK

· France

· Spain

· Italy

Rest of Europe

Company Profiles

· Alvion Pharmaceuticals P.C

· Fresenius SE & Co. KGaA

· GlaxoSmithKline plc

· Hikma Pharmaceuticals PLC

· Lupin Ltd.

· Mylan N.V.

· Novartis International AG

· Novo Nordisk A/S

· StadaArzneimittel AG

· Teva Pharmaceutical Industries Ltd.

Reasons to buy from us –

1. We cover more than 15 major industries, further segmented into more than 90 sectors.

2. More than 120 countries are for analysis.

3. Over 100+ paid data sources mined for investigation.

4. Our expert research analysts answer all your questions before and after purchasing your report.

For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/europe-generic-drugs-market

Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404

About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.

This release was published on openPR.